Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

Regulatory peptides 20121110

Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.

Journal of clinical pharmacology 20121001

Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.

Diabetes, obesity & metabolism 20121001

Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes.

Diabetes, obesity & metabolism 20121001

No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.

Diabetes, obesity & metabolism 20121001

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.

Diabetes research and clinical practice 20121001

Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.

Diabetes care 20121001

Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose?

Diabetes technology & therapeutics 20121001

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.

Diabetes & metabolism 20121001

Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy.

Journal of cardiac failure 20121001

Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers.

Advances in therapy 20121001

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.

Diabetes, obesity & metabolism 20120901

Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells.

Diabetes, obesity & metabolism 20120901

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.

Journal of diabetes 20120901

Sitagliptin exerts anti-inflammatory and anti-allergic effects in ovalbumin-induced murine model of allergic airway disease.

Naunyn-Schmiedeberg's archives of pharmacology 20120901

Sitagliptin exerts an antinflammatory action.

The Journal of clinical endocrinology and metabolism 20120901

Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells.

Hypertension (Dallas, Tex. : 1979) 20120901

Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.

Hypertension (Dallas, Tex. : 1979) 20120901

[Nephropathy and metabolic heart diseases. Cardiac risk in kidney malfunction].

MMW Fortschritte der Medizin 20120823

Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study.

Clinical endocrinology 20120801

Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor.

The Journal of dermatology 20120801

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

Diabetes, obesity & metabolism 20120801

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.

Diabetes, obesity & metabolism 20120801

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.

Diabetologia 20120801

Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes.

The Journal of clinical endocrinology and metabolism 20120801

Lower risk of hypoglycemia with sitagliptin compared to glipizide when either is added to metformin therapy: a pre-specified analysis adjusting for the most recently measured HbA(1c) value.

Current medical research and opinion 20120801

The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.

Alimentary pharmacology & therapeutics 20120801

Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.

Current medical research and opinion 20120801

Mechanism of action of DPP-4 inhibitors--new insights.

The Journal of clinical endocrinology and metabolism 20120801

Exenatide and sitagliptin are not associated with increased risk of acute renal failure: a retrospective claims analysis.

Diabetes, obesity & metabolism 20120701

Sitagliptin promotes macrophage-to-faeces reverse cholesterol transport through reduced intestinal cholesterol absorption in obese insulin resistant CETP-apoB100 transgenic mice.

Diabetes, obesity & metabolism 20120701

The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.

Diabetes technology & therapeutics 20120701

Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.

Current medical research and opinion 20120701

Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.

Current medical research and opinion 20120701

[Liraglutide: new results in the treatment of type 2 diabetes mellitus].

Drugs of today (Barcelona, Spain : 1998) 20120701

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

Lancet (London, England) 20120616

Choosing a blood-glucose-lowering agent after metformin.

Lancet (London, England) 20120616

Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120615

[Efficacy of tianmaixiaoke tablets in the treatment of newly diagnosed type 2 diabetes mellitus in China].

Zhonghua yi xue za zhi 20120612

Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.

Acta diabetologica 20120601

Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis.

Diabetes, obesity & metabolism 20120601

Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.

Expert opinion on drug metabolism & toxicology 20120601

Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis.

Acta gastro-enterologica Belgica 20120601

Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction.

Diabetic medicine : a journal of the British Diabetic Association 20120501

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

Diabetes, obesity & metabolism 20120501

Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.

Diabetes, obesity & metabolism 20120501

Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers.

European journal of clinical pharmacology 20120501

An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.

Current diabetes reviews 20120501

Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes.

International journal of clinical practice 20120501

Immunotherapies in diabetes mellitus type 1.

The Medical clinics of North America 20120501

Association between sitagliptin adherence and self-monitoring of blood glucose.

Journal of diabetes science and technology 20120501

Decreased hepatic glucose production in obese rats by dipeptidyl peptidase-IV inhibitor sitagliptin.

Chinese medical journal 20120501

The combination of colesevelam with sitagliptin enhances glycemic control in diabetic ZDF rat model.

American journal of physiology. Gastrointestinal and liver physiology 20120415

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Diabetes & metabolism 20120401

Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures.

Neurobiology of disease 20120401

The design of the liraglutide clinical trial programme.

Diabetes, obesity & metabolism 20120401

Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.

Diabetic medicine : a journal of the British Diabetic Association 20120301

Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone.

The Journal of the Association of Physicians of India 20120301

Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation.

Oncogene 20120223

The importance of green chemistry in process research and development.

Chemical Society reviews 20120221

Persistent edematous-plaque photosensitivity observed with sitagliptin phosphate (Januvia®).

Dermatology online journal 20120215

Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes.

Diabetes research and clinical practice 20120201

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning.

Experimental hematology 20120201

Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.

Endocrinology 20120201

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.

Diabetes care 20120201

Psoriasiform eruption triggered by a dipeptidyl peptidase IV inhibitor.

The Australasian journal of dermatology 20120201

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

Journal of the American College of Cardiology 20120117

Dipeptidyl peptidase-4 inhibitor: another player for cardiovascular protection.

Journal of the American College of Cardiology 20120117

Evaluation of Modification of Diet in Renal Disease Study and Cockcroft-Gault equations for sitagliptin dosing.

Journal of nephrology 20120101

Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure.

European journal of heart failure 20120101

Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.

Diabetes, obesity & metabolism 20120101

The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes.

Diabetes research and clinical practice 20120101

Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis.

Dermatology (Basel, Switzerland) 20120101

Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

Why do metabolites circulate?

Xenobiotica; the fate of foreign compounds in biological systems 20120101

Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.

Translational research : the journal of laboratory and clinical medicine 20120101

Non-alcoholic fatty liver disease adversely affects the glycemic control afforded by sitagliptin.

Hepato-gastroenterology 20120101

Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan.

Endocrine journal 20120101

[The new antidiabetic agents in the firing line.... safety reasons or witch hunt?].

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20120101

Suicide attempt by an overdose of sitagliptin, an oral hypoglycemic agent: a case report and a review of the literature.

Endocrine journal 20120101

Sitagliptin in glutamic acid decarboxylase antibody-positive diabetes mellitus.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.

Journal of medical economics 20120101

Intentional weight loss and dose reductions of anti-diabetic medications--a retrospective cohort study.

PloS one 20120101

Reversible mitral and aortic regurgitation due to pioglitazone.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20120101

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.

BMC pharmacology 20120101

Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.

PloS one 20120101

Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.

CANNT journal = Journal ACITN 20120101

A new preventive strategy for hypoglycemia incorporating added food diet in patients with type 2 diabetes who received sitagliptin therapy.

Endocrine research 20120101

Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.

Journal of medical economics 20120101

Sitagliptin (DPP-4 inhibitor)-induced rheumatoid arthritis in type 2 diabetes mellitus: a case report.

Internal medicine (Tokyo, Japan) 20120101

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

Cardiovascular diabetology 20120101

The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone.

TheScientificWorldJournal 20120101

Combination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.

Pharmacology 20120101

The effects of simvastatin on the pharmacokinectics of sitagliptin.

Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique 20120101

Effects of DPP-4 inhibition on cardiac metabolism and function in mice.

Journal of molecular and cellular cardiology 20111201

Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation.

Transplantation 20111127

[Incretin-based therapy for treating patients with type 2 diabetes].

Orvosi hetilap 20111127

Sitagliptin and simvastatin (juvisync).

The Medical letter on drugs and therapeutics 20111114

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study.

Diabetes, obesity & metabolism 20111101

Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes.

Diabetes technology & therapeutics 20111101

Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.

Diabetes research and clinical practice 20111101

Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222.

Xenobiotica; the fate of foreign compounds in biological systems 20111101

The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.

International journal of clinical practice 20111101

Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.

Prescrire international 20111101

Both sitagliptin analogue & pioglitazone preserve the beta-cell proportion in the islets with different mechanism in non-obese and obese diabetic mice.

BMB reports 20111101

[Sitagliptin in the treatment of type 2 diabetes: new data presented during the American Diabetes Association annual meeting (San Diego, California, June 2011)].

Drugs of today (Barcelona, Spain : 1998) 20111101

Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial.

Diabetic medicine : a journal of the British Diabetic Association 20111001

Evaluation of the interaction between sitagliptin and cyclodextrin derivatives by capillary electrophoresis and nuclear magnetic resonance spectroscopy.

Electrophoresis 20111001

[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].

Orvosi hetilap 20110911

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not affect the pharmacokinetics of ethinyl estradiol or norethindrone in healthy female subjects.

Journal of clinical pharmacology 20110901

Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.

Expert opinion on pharmacotherapy 20110901

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

Diabetes, obesity & metabolism 20110901

The metabolic syndrome influences the response to incretin-based therapies.

Acta diabetologica 20110901

Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.

International journal of clinical practice 20110901

Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20110901

Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal?

Journal of medicinal chemistry 20110825

Development of a molecularly imprinted polymer for selective extraction followed by liquid chromatographic determination of sitagliptin in rat plasma and urine.

Talanta 20110815

Merging the best of two worlds: artificial metalloenzymes for enantioselective catalysis.

Chemical communications (Cambridge, England) 20110814

Inhibition of anaphylaxis like reaction and mast cell activation by Sitagliptin.

International immunopharmacology 20110801

DPP-IV inhibitor may affect spermatogenesis.

Diabetes research and clinical practice 20110801

Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.

Endocrinology 20110801

Improved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptin.

Pancreas 20110801

Protective effects of dipeptidyl peptidase-4 (DPP-4) inhibitor against increased β cell apoptosis induced by dietary sucrose and linoleic acid in mice with diabetes.

The Journal of biological chemistry 20110722

Liquid chromatographic determination of sitagliptin either alone or in ternary mixture with metformin and sitagliptin degradation product.

Talanta 20110715

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

Gastroenterology 20110701

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

Diabetes, obesity & metabolism 20110701

Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide.

Diabetes research and clinical practice 20110701

Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.

Diabetes technology & therapeutics 20110701

Pancreatic ultrastructural enhancement due to telmisartan plus sitagliptin treatment in diet-induced obese C57BL/6 mice.

Pancreas 20110701

Sitagliptin: a review.

Expert opinion on pharmacotherapy 20110701

GLP-1-based therapies: the dilemma of uncertainty.

Gastroenterology 20110701

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.

The Annals of pharmacotherapy 20110701

Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?

British journal of hospital medicine (London, England : 2005) 20110701

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.

Diabetic medicine : a journal of the British Diabetic Association 20110601

Simultaneous quantitation of metformin and sitagliptin from mouse and human dried blood spots using laser diode thermal desorption tandem mass spectrometry.

Journal of pharmaceutical and biomedical analysis 20110601

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus.

Journal of the American Geriatrics Society 20110601

Successful long-term use of sitagliptin for the treatment of new-onset diabetes mellitus after solid organ transplantation: a case report.

Transplantation proceedings 20110601

[Determination of sitagliptin phosphate in rat plasma by ultra high performance liquid chromatography-tandem mass spectrometry].

Se pu = Chinese journal of chromatography 20110601

An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.

Contemporary clinical trials 20110501

Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.

Diabetes research and clinical practice 20110501

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Current medical research and opinion 20110501

[Incretin enhancer: sitagliptin].

Nihon rinsho. Japanese journal of clinical medicine 20110501

Journal withdraws article after complaints from drug manufacturers.

BMJ (Clinical research ed.) 20110411

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

Diabetes, obesity & metabolism 20110401

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.

International journal of clinical practice 20110401

[Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].

Wiener klinische Wochenschrift 20110401

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats.

Journal of hypertension 20110301

Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries.

Biological chemistry 20110301

Substance P-induced skin inflammation is not modulated by a single dose of sitagliptin in human volunteers.

Biological chemistry 20110301

Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.

Diabetes, obesity & metabolism 20110301

Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.

British journal of clinical pharmacology 20110301

Sitagliptin and metformin--novel combination therapy.

Expert opinion on pharmacotherapy 20110301

Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.

Diabetic medicine : a journal of the British Diabetic Association 20110301

Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats.

Experimental biology and medicine (Maywood, N.J.) 20110301

A diabetes drug, sitagliptin, also has a potential to prevent diabetes.

Experimental biology and medicine (Maywood, N.J.) 20110301

Sitagliptin manufacture: a compelling tale of green chemistry, process intensification, and industrial asymmetric catalysis.

Angewandte Chemie (International ed. in English) 20110225

Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.

Drugs 20110212

Severe leucopenia associated with Sitagliptin use.

Diabetes research and clinical practice 20110201

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.

American journal of physiology. Endocrinology and metabolism 20110201

Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.

Endocrinology 20110201

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

Diabetes, obesity & metabolism 20110201

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

International journal of clinical practice 20110201

Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.

Diabetes care 20110201

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.

The Tohoku journal of experimental medicine 20110201

Pharmacology of GLP-1 agonists: describing the therapeutic potential to patients.

The Journal of the American Osteopathic Association 20110201

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

Hospital practice (1995) 20110201

Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.

Journal of medicinal chemistry 20110127

Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes.

Regulatory peptides 20110117

Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats.

Clinical science (London, England : 1979) 20110101

Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects.

Diabetes, obesity & metabolism 20110101

Effectiveness of sitagliptin in asian Indian patients with type 2 diabetes-an Indian tertiary diabetes care center experience.

Diabetes technology & therapeutics 20110101

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

Endocrine journal 20110101

Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.

Postgraduate medicine 20110101

A case of drug-induced hepatic injury associated with sitagliptin.

Internal medicine (Tokyo, Japan) 20110101

Sitagliptin compared with thiazolidinediones as a third-line oral antihyperglycemic agent in type 2 diabetes mellitus.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20110101

Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.

Clinical drug investigation 20110101

[Glycemic control before and after sitagliptin in general medical practice: analysis of determinant factors in the Belgian observational study 'SUGAR'].

Revue medicale de Liege 20110101

Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus.

Hepato-gastroenterology 20110101

Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.

PloS one 20110101

A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.

Cardiovascular diabetology 20110101

Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).

Experimental diabetes research 20110101

Sitagliptin attenuates metformin-mediated AMPK phosphorylation through inhibition of organic cation transporters.

Xenobiotica; the fate of foreign compounds in biological systems 20101201

[Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].

Drugs of today (Barcelona, Spain : 1998) 20101201

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)--rationale, design and first interim analysis.

International journal of cardiology 20101119

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.

Diabetes care 20101101

DPP-4 inhibitors: what may be the clinical differentiators?

Diabetes research and clinical practice 20101101

Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.

International journal of clinical practice 20101101

[New data from the US-American Diabetes Congress. GLP-1 effect: more than reducing blood glucose].

MMW Fortschritte der Medizin 20101007

Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.

Hypertension (Dallas, Tex. : 1979) 20101001

Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.

Hypertension (Dallas, Tex. : 1979) 20101001

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.

Expert opinion on drug metabolism & toxicology 20101001

Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired fasting glucose.

Diabetes research and clinical practice 20101001

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.

Diabetes/metabolism research and reviews 20101001

Initial short-term intensive insulin therapy as a strategy for evaluating the preservation of beta-cell function with oral antidiabetic medications: a pilot study with sitagliptin.

Diabetes, obesity & metabolism 20101001

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.

Clinical pharmacokinetics 20100901

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.